The DOI matches its Crossref record; 280 of the 280 references it cites were found in a registry or an index.
Control of human toxoplasmosis
Open accessAbstract
Toxoplasmosis is caused by Toxoplasma gondii, an apicomplexan parasite that is able to infect any nucleated cell in any warm-blooded animal. Toxoplasma gondii infects around 2 billion people and, whilst only a small percentage of infected people will suffer serious disease, the prevalence of the parasite makes it one of the most damaging zoonotic diseases in the world. Toxoplasmosis is a disease with multiple manifestations: it can cause a fatal encephalitis in immunosuppressed people; if first contracted during pregnancy, it can cause miscarriage or congenital defects in the neonate; and it can cause serious ocular disease, even in immunocompetent people. The disease has a complex epidemiology, being transmitted by ingestion of oocysts that are shed in the faeces of definitive feline hosts and contaminate water, soil and crops, or by consumption of intracellular cysts in undercooked meat from intermediate hosts. In this review we examine current and future approaches to control toxoplasmosis, which encompass a variety of measures that target different components of the life cycle of T. gondii. These include: education programs about the parasite and avoidance of contact with infectious stages; biosecurity and sanitation to ensure food and water safety; chemo- and immunotherapeutics to control active infections and disease; prophylactic options to prevent acquisition of infection by livestock and cyst formation in meat; and vaccines to prevent shedding of oocysts by definitive feline hosts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxoplasma gondii: from animals to humans
Tenter, A. M., Heckeroth, A. R., & Weiss, L. M. (2000) · International Journal for Parasitology · doi:10.1016/s0020-7519(00)00124-7 · Cited by 3,702
Montoya, J., & Liesenfeld, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16412-x · Cited by 3,232
Trained immunity: A program of innate immune memory in health and– disease
Netea, M. G., Joosten, L. A. B., Latz, E., Mills, K. H. G., Natoli, G., Stunnenberg, H. G., O’Neill, L. A. J., & Xavier, R. J. (2016) · Science · doi:10.1126/science.aaf1098 · Cited by 2,768
Defining trained immunity and its role in health and disease
Netea, M. G., Domínguez-Andrés, J., Barreiro, L. B., Chavakis, T., Divangahi, M., Fuchs, E., Joosten, L. A. B., van der Meer, J. W. M., Mhlanga, M. M., Mulder, W. J. M., et al. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0285-6 · Cited by 2,690
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910607 · Cited by 2,217
Toxoplasmic Encephalitis in AIDS
Luft, B. J., & Remington, J. S. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/15.2.211 · Cited by 1,287
BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis
Kaufmann, E., Sanz, J., Dunn, J. L., Khan, N., Mendonça, L. E., Pacis, A., Tzelepis, F., Pernet, E., Dumaine, A., Grenier, J.-C., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.031 · Cited by 1,191
Arts, R. J. W., Moorlag, S. J. C. F. M., Novakovic, B., Li, Y., Wang, S.-Y., Oosting, M., Kumar, V., Xavier, R. J., Wijmenga, C., Joosten, L. A. B., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2017.12.010 · Cited by 1,179
Interferon-γ: the Major Mediator of Resistance Against Toxoplasma gondii
Suzuki, Y., Orellana, M. A., Schreiber, R. D., & Remington, J. S. (1988) · Science · doi:10.1126/science.3128869 · Cited by 1,173
Inhibitors of the Nonmevalonate Pathway of Isoprenoid Biosynthesis as Antimalarial Drugs
Jomaa, H., Wiesner, J., Sanderbrand, S., Altincicek, B., Weidemeyer, C., Hintz, M., Türbachova, I., Eberl, M., Zeidler, J., Lichtenthaler, H. K., et al. (1999) · Science · doi:10.1126/science.285.5433.1573 · Cited by 1,173
Research works printed but not linked: 97
- Abdelbaset, 2017, Lactate dehydrogenase in Toxoplasma gondii controls virulence, bradyzoite differentiation, and chronic infection, PLoS ONE, 12, 10.1371/journal.pone.0173745 · doi:10.1371/journal.pone.0173745
- Adeyemi, 2018, Screening of chemical compound libraries identified new anti-Toxoplasma gondii agents, Parasitol. Res., 117, 355, 10.1007/s00436-017-5698-1 · doi:10.1007/s00436-017-5698-1
- Adeyemi, 2019, Nanoparticles show potential to retard bradyzoites in vitro formation of Toxoplasma gondii, Folia Parasitol., 66, 001, 10.14411/fp.2019.001 · doi:10.14411/fp.2019.001
- Alajmi, 2019, Anti-Toxoplasma activity of silver nanoparticles green synthesizes with Phoenix dactylifera and Ziziphus spina-christi extracts which inhibits inflammation through liver regulation of cytokines in Balb/c mice, Biosci. Rep., 39, 10.1042/BSR20190379 · doi:10.1042/bsr20190379
- Aly, 2018, Advantages of bioconjugated silica-coated nanoparticles as an innovative diagnosis for human toxoplasmosis, Acta Tropica, 177, 19, 10.1016/j.actatropica.2017.09.024 · doi:10.1016/j.actatropica.2017.09.024
- Amberg-Johnson, 2019, Host cell metabolism contributes to delayed-death kinetics of apicoplast inhibitors in Toxoplasma gondii, Antimicrob. Agents Chemother., 63, 10.1128/AAC.01646-18 · doi:10.1128/aac.01646-18
- Anand, 2015, Oral administration of encapsulated bovine lactoferrin nanocapsules against intracellular parasite Toxoplasma gondii, Int. J. Nanomed., 10, 6355
- Araujo, 1997, Treatment with interleukin 12 in combination with atovaquone or clindamycin significantly increases survival of mice with acute toxoplasmosis, Antimicrob. Agents Chemother., 41, 188, 10.1128/AAC.41.1.188 · doi:10.1128/aac.41.1.188
- Araujo, 1992, In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii, Antimicrob. Agents Chemother., 36, 326, 10.1128/AAC.36.2.326 · doi:10.1128/aac.36.2.326
- Araujo, 1974, Effect of clindamycin on acute and chronic toxoplasmosis in mice, Antimicrob. Agents Chemother., 5, 647, 10.1128/AAC.5.6.647 · doi:10.1128/aac.5.6.647
- Baatz, 2006, Reactivation of Toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient, Ocular Immunol. Inflamm., 14, 185, 10.1080/09273940600659740 · doi:10.1080/09273940600659740
- Balaskas, 2012, Azithromycin versus sulfadiazine and pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study, Med. Sci. Monitor, 18, CR296, 10.12659/MSM.882735 · doi:10.12659/msm.882735
- Benedetto, 1991, Effect of rIFN-gamma and IL-2 treatments in mouse and nude rat infections with Toxoplasma gondii, Eur. Cytokine Netw., 2, 107
- Bhadra, 2012, IL-7 and IL-15 do not synergize during CD8 T cell recall response against an obligate intracellular parasite, Microbes Infect., 14, 1160, 10.1016/j.micinf.2012.07.018 · doi:10.1016/j.micinf.2012.07.018
- Bosch-Driessen, 2002, A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis, American J. Ophthalmol., 134, 34, 10.1016/S0002-9394(02)01537-4 · doi:10.1016/s0002-9394(02)01537-4
- Brenier-Pinchart, 2006, The Toxoplasma surface protein SAG1 triggers efficient in vitro secretion of chemokine ligand 2 (CCL2) from human fibroblasts, Microbes Infect., 8, 254, 10.1016/j.micinf.2005.06.023 · doi:10.1016/j.micinf.2005.06.023
- Buxton, 1994, Primary and secondary responses of the ovine lymph node to Toxoplasma gondii: cell output in efferent lymph and parasite detection, J. Comp. Pathol., 111, 231, 10.1016/S0021-9975(05)80002-7 · doi:10.1016/s0021-9975(05)80002-7
- Buyukbaba Boral, 2012, Investigation of combined effectiveness of spiramycin and beta-glucan in mice models of acute toxoplasmosis and determination of IL-10, IL-12 and TNF-alpha levels, Mikrobiyoloji bulteni, 46, 446
- Camps, 2002, An rRNA mutation identifies the apicoplast as the target for clindamycin in Toxoplasma gondii, Mol. Microbiol., 43, 1309, 10.1046/j.1365-2958.2002.02825.x · doi:10.1046/j.1365-2958.2002.02825.x
- Carellos, 2014, Adverse socioeconomic conditions and oocyst-related factors are associated with congenital toxoplasmosis in a population-based study in Minas Gerais, Brazil, PLoS One, 9, 10.1371/journal.pone.0088588 · doi:10.1371/journal.pone.0088588
- Choromanski, 1995, Safety and efficacy of modified live feline Toxoplasma gondii vaccine, Dev. Biol. Stand., 84, 269
- da Cunha, 2012, Humoral and cellular immune responses in pigs immunized intranasally with crude rhoptry proteins of Toxoplasma gondii plus Quil-A, Vet. Parasitol., 186, 216, 10.1016/j.vetpar.2011.11.034 · doi:10.1016/j.vetpar.2011.11.034
- Delemarre, 1994, Effect of IFN-gamma on the proliferation of Toxoplasma gondii in monocytes and monocyte-derived macrophages from AIDS patients, Immunology, 83, 646
- Delemarre, 1993, Restoration of the toxoplasmastatic activity of monocytes from AIDS patients during in vivo treatment with interferon-gamma, J. Infect. Dis., 168, 516, 10.1093/infdis/168.2.516 · doi:10.1093/infdis/168.2.516
- Doggett, 2020, Orally bioavailable endochin-like quinolone carbonate ester prodrug reduces Toxoplasma gondii brain cysts, Antimicrob. Agents Chemother., 64, e00535, 10.1128/AAC.00535-20 · doi:10.1128/aac.00535-20
- Dubey, 2017, Schizogony and gametogony of oocyst-deficient T-263 strain of Toxoplasma gondii, Vet. Parasitol., 245, 160, 10.1016/j.vetpar.2017.05.024 · doi:10.1016/j.vetpar.2017.05.024
- Dubey, 1994, Persistence of immunity to toxoplasmosis in pigs vaccinated with a nonpersistent strain of Toxoplasma gondii, Am. J. Vet. Res., 55, 982, 10.2460/ajvr.1994.55.07.982 · doi:10.2460/ajvr.1994.55.07.982
- Dubey, 1998, Immunity to toxoplasmosis in pigs fed irradiated Toxoplasma gondii oocysts, J. Parasitol., 84, 749, 10.2307/3284582 · doi:10.2307/3284582
- Dumas, 1994, Evaluation of the efficacy of prolonged administration of azithromycin in a murine model of chronic toxoplasmosis, J. Antimicrob. Chemother., 34, 111, 10.1093/jac/34.1.111 · doi:10.1093/jac/34.1.111
- Ferguson, 1994, An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii, Int. J. Exp. Pathol., 75, 111
- Frenkel, 1967, Adoptive immunity to intracellular infection, J. Immunol., 98, 1309, 10.4049/jimmunol.98.6.1309 · doi:10.4049/jimmunol.98.6.1309
- Freppel, 2019, Structure, composition, and roles of the Toxoplasma gondii oocyst and sporocyst walls, Cell Surf., 5, 10016, 10.1016/j.tcsw.2018.100016 · doi:10.1016/j.tcsw.2018.100016
- Freyre, 2007, Toxoplasma gondii: cross-immunity against the enteric cycle, Exp. Parasitol., 115, 48, 10.1016/j.exppara.2006.05.007 · doi:10.1016/j.exppara.2006.05.007
- Fu, 2011, Generation of a neutralizing human monoclonal antibody Fab fragment to surface antigen 1 of Toxoplasma gondii tachyzoites, Infect. Immun., 79, 512, 10.1128/IAI.00969-10 · doi:10.1128/iai.00969-10
- Gao, 2018, Immune response and protective effect against chronic Toxoplasma gondii infection induced by vaccination with a DNA vaccine encoding profilin, BMC Infect. Dis., 18, 117, 10.1186/s12879-018-3022-z · doi:10.1186/s12879-018-3022-z
- Gasparotto Junior, 2016, Effects of extracts from Echinacea purpurea (L) MOENCH on mice infected with different strains of Toxoplasma gondii, Parasitol. Res., 115, 3999, 10.1007/s00436-016-5167-2 · doi:10.1007/s00436-016-5167-2
- Hagras, 2019, Successful treatment of acute experimental toxoplasmosis by spiramycin-loaded chitosan nanoparticles, Exp. Parasitol., 204, 10.1016/j.exppara.2019.107717 · doi:10.1016/j.exppara.2019.107717
- Haverkos, 1987, Assessment of therapy for toxoplasma encephalitis. The TE Study Group, Am J. Med., 82, 907, 10.1016/0002-9343(87)90151-3 · doi:10.1016/0002-9343(87)90151-3
- Hegazy, 2015, Novel IMB-ELISA assay for rapid diagnosis of human toxoplasmosis using SAG-1 antigen, Jpn. J. Infect. Dis., 68, 474, 10.7883/yoken.JJID.2014.444 · doi:10.7883/yoken.jjid.2014.444
- Ivanetich, 1990, Thymidylate synthase-dihydrofolate reductase in protozoa, Exp. Parasitol., 70, 367, 10.1016/0014-4894(90)90119-W · doi:10.1016/0014-4894(90)90119-w
- Jiang, 2013, A novel immunosensor for detecting Toxoplasma gondii-specific IgM based on goldmag nanoparticles and graphene sheets, Colloids Surf., B Biointerfaces, 101, 481, 10.1016/j.colsurfb.2012.07.021 · doi:10.1016/j.colsurfb.2012.07.021
- Jiang, 2012, An agent-based model for the transmission dynamics of Toxoplasma gondii, J. Theoret. Biol., 293, 15, 10.1016/j.jtbi.2011.10.006 · doi:10.1016/j.jtbi.2011.10.006
- Kasper, 1995, IL-7 stimulates protective immunity in mice against the intracellular pathogen, Toxoplasma gondii, J. Immunol., 155, 4798, 10.4049/jimmunol.155.10.4798 · doi:10.4049/jimmunol.155.10.4798
- Katlama, 1996, Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group, AIDS, 10, 1107
- Kersten, 2019, Unexpected neurologic complications following a novel lymphoma treatment 'expected' to give rise to neurologic toxicity, BMJ Case Rep., 12, 10.1136/bcr-2019-229946 · doi:10.1136/bcr-2019-229946
- Keyhani, 2020, Biogenic selenium nanoparticles target chronic toxoplasmosis with minimal cytotoxicity in a mouse model, J. Med. Microbiol., 69, 104, 10.1099/jmm.0.001111 · doi:10.1099/jmm.0.001111
- Kim, 2007, Bradyzoite-specific surface antigen SRS9 plays a role in maintaining Toxoplasma gondii persistence in the brain and in host control of parasite replication in the intestine, Infect. Immun., 75, 1626, 10.1128/IAI.01862-06 · doi:10.1128/iai.01862-06
- Kochanowsky, 2020, A single transcription factor drives Toxoplasma gondii differentiation, Cell, 180, 216, 10.1016/j.cell.2019.12.038 · doi:10.1016/j.cell.2019.12.038
- Konrad, 2013, Inhibitors of eIF2α dephosphorylation slow replication and stabilize latency in Toxoplasma gondii, Antimicrob. Agents Chemoth., 57, 1815, 10.1128/AAC.01899-12 · doi:10.1128/aac.01899-12
- Liang, 2020, Acquisition of exogenous fatty acids renders apicoplast-based biosynthesis dispensable in tachyzoites of Toxoplasma, J. Biol. Chem., 295, 7743, 10.1074/jbc.RA120.013004 · doi:10.1074/jbc.ra120.013004
- Lieberman, 2004, Interleukin-15-deficient mice develop protective immunity to Toxoplasma gondii, Infect. Immun., 72, 6729, 10.1128/IAI.72.11.6729-6732.2004 · doi:10.1128/iai.72.11.6729-6732.2004
- Ling, 2007, The farnesyl-diphosphate/geranylgeranyl-diphosphate synthase of Toxoplasma gondii is a bifunctional enzyme and a molecular target of bisphosphonates, J. Biol. Chem., 282, 30804, 10.1074/jbc.M703178200 · doi:10.1074/jbc.m703178200
- Ling, 2005, Bisphosphonate inhibitors of Toxoplasma gondii growth: in vitro, QSAR, and in vivo investigations, J. Med. Chem., 48, 3130, 10.1021/jm040132t · doi:10.1021/jm040132t
- Long, 2016, Analysis of noncanonical calcium-dependent protein kinases in Toxoplasma gondii by targeted gene deletion using CRISPR/Cas9, Infect. Immun., 84, 1262, 10.1128/IAI.01173-15 · doi:10.1128/iai.01173-15
- Machala, 2015, Toxoplasmosis in immunocompromised patients, Epidemiol. Mikrobiol. Imunol., 64, 59
- Mareze, 2019, Socioeconomic vulnerability associated to Toxoplasma gondii exposure in southern Brazil, PLoS One, 14, 10.1371/journal.pone.0212375 · doi:10.1371/journal.pone.0212375
- Martin, 2001, Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy, J. Med. Chem., 44, 909, 10.1021/jm0002578 · doi:10.1021/jm0002578
- Martorelli Di Genova, 2019, Intestinal-delta-6-desaturase activity determines hots range for Toxoplasma sexual reproduction, PLoS Biol., 17, 10.1371/journal.pbio.3000364 · doi:10.1371/journal.pbio.3000364
- Martynowicz, 2020, Efficacy of guanabenz combination therapy against chronic toxoplasmosis across multiple mouse strains, Antimicrob. Agents Chemother., 10.1128/AAC.00539-20 · doi:10.1128/aac.00539-20
- Mateus-Pinilla, 2002, A computer simulation of the prevention of the transmission of Toxoplasma gondii on swine farms using a feline T. gondii vaccine, Prev. Vet. Med., 55, 17, 10.1016/S0167-5877(02)00057-0 · doi:10.1016/s0167-5877(02)00057-0
- McLeod, 2006, Severe sulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis, Pediatr. Infect. Dis. J., 25, 270, 10.1097/01.inf.0000202070.59190.9a · doi:10.1097/01.inf.0000202070.59190.9a
- McLeod, 2014, Management of congenital toxoplasmosis, Curr. Pediatr. Rep., 2, 166, 10.1007/s40124-014-0055-7 · doi:10.1007/s40124-014-0055-7
- Medawar-Aguilar, 2019, Serological diagnosis of toxoplasmosis disease using a fluorescent immunosensor with chitosan-ZnO-nanoparticles, Anal. Biochem., 564–565, 116, 10.1016/j.ab.2018.10.025 · doi:10.1016/j.ab.2018.10.025
- Megged, 2008, Breakthrough cerebral toxoplasmosis in a patient receiving atovaquone prophylaxis after a hematopoietic stem cell transplantation, Pediatr. Transplant., 12, 902, 10.1111/j.1399-3046.2007.00891.x · doi:10.1111/j.1399-3046.2007.00891.x
- Mui, 2005, Triazine Inhibits Toxoplasma gondii tachyzoites in vitro and in vivo, Antimicrob. Agents Chemother., 49, 3463, 10.1128/AAC.49.8.3463-3467.2005 · doi:10.1128/aac.49.8.3463-3467.2005
- Mui, 2008, Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo, PLoS Neglect. Trop. Dis., 2, 10.1371/journal.pntd.0000190 · doi:10.1371/journal.pntd.0000190
- Narasimhan, 2008, Translation regulation by eukaryotic initiation factor-2 kinases in the development of latent cysts in Toxoplasma gondii, J. Biol. Chem., 283, 16591, 10.1074/jbc.M800681200 · doi:10.1074/jbc.m800681200
- Nishimura, 2017, CCR5 Is involved in interruption of pregnancy in mice infected with Toxoplasma gondii during early pregnancy, Infect. Immun., 85, e00257, 10.1128/IAI.00257-17 · doi:10.1128/iai.00257-17
- Nogareda, 2014, Incidence and prevalence of Toxoplasma gondii infection in France, 1980–2020: model-based estimation, Epidemiol. Infect., 142, 1661, 10.1017/S0950268813002756 · doi:10.1017/s0950268813002756
- O'Connell, 1988, Toxoplasmosis in sheep. II. The ability of a live vaccine to prevent lamb losses after an intravenous challenge with Toxoplasma gondii, NZ Vet. J., 36, 1, 10.1080/00480169.1988.35461 · doi:10.1080/00480169.1988.35461
- Omata, 1996, Toxoplasma gondii: experimental infection in cats vaccinated with 60Co-irradiated tachyzoites, Vet. Parasitol., 65, 173, 10.1016/S0304-4017(96)00973-9 · doi:10.1016/s0304-4017(96)00973-9
- Pearson, 1999, Atovaquone for the treatment of Toxoplasma retinochoroiditis in immunocompetent patients, Ophthalmology, 106, 148, 10.1016/S0161-6420(99)90021-0 · doi:10.1016/s0161-6420(99)90021-0
- Pfefferkorn, 1993, Mutants of Toxoplasma gondii resistant to atovaquone (566C80) or decoquinate, J. Parasitol., 79, 559, 10.2307/3283383 · doi:10.2307/3283383
- Pfefferkorn, 1983, Toxoplasma gondii: genetic crosses reveal phenotypic suppression of hydroxyurea resistance by fluorodeoxyuridine resistance, Exp. Parasitol., 55, 207, 10.1016/0014-4894(83)90015-2 · doi:10.1016/0014-4894(83)90015-2
- Pfefferkorn, 1992, Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant, Antimicrob. Agents Chemother., 36, 1091, 10.1128/AAC.36.5.1091 · doi:10.1128/aac.36.5.1091
- Pott, 2013, Isolated cerebellar toxoplasmosis as a complication of HIV infection, Int. J. STD AIDS, 24, 70, 10.1258/ijsa.2012.012189 · doi:10.1258/ijsa.2012.012189
- Romand, 1993, In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii, Antimicrob. Agents Chemother., 37, 2371, 10.1128/AAC.37.11.2371 · doi:10.1128/aac.37.11.2371
- Rothova, 1998, Azithromycin for ocular toxoplasmosis, Br. J. Ophthalmol., 82, 1306, 10.1136/bjo.82.11.1306 · doi:10.1136/bjo.82.11.1306
- Serranti, 2011, Congenital toxoplasmosis treatment, Eur. Rev. Med. Pharmacol. Sci., 15, 193
- Shakibaie, 2020, Prophylactic effects of biogenic selenium nanoparticles on acute toxoplasmosis: an in vivo study, Ann. Med. Surg., 54, 85, 10.1016/j.amsu.2020.04.010 · doi:10.1016/j.amsu.2020.04.010
- Sharif, 2016, The efficacy of herbal medicines against Toxoplasma gondii during the last 3 decades: a systematic review, Can. J. Physiol. Pharmacol., 94, 1237, 10.1139/cjpp-2016-0039 · doi:10.1139/cjpp-2016-0039
- Shubar, 2008, A new combined flow-cytometry-based assay reveals excellent activity against Toxoplasma gondii and low toxicity of new bisphosphonates in vitro and in vivo, J. Antimicrob. Chemother., 61, 1110, 10.1093/jac/dkn047 · doi:10.1093/jac/dkn047
- Singh, 2014, Serologic prevalence of Toxoplasma gondii in Indian women of child bearing age and effects of social and environmental factors, PLoS Negl. Trop. Dis., 8, 10.1371/journal.pntd.0002737 · doi:10.1371/journal.pntd.0002737
- Sullivan, 2004, Parasite-specific eIF2 (eukaryotic initiation factor-2) kinase required for stress-induced translation control, Biochem. J., 380, 523, 10.1042/bj20040262 · doi:10.1042/bj20040262
- Suzuki, 1990, The effect of anti-IFN-gamma antibody on the protective effect of Lyt-2+ immune T cells against toxoplasmosis in mice, J. Immunol., 144, 1954, 10.4049/jimmunol.144.5.1954 · doi:10.4049/jimmunol.144.5.1954
- Tu, 2020, MAG2, a Toxoplasma gondii bradyzoite stage-specific cyst matrix protein, mSphere, 5, e00100, 10.1128/mSphere.00100-20 · doi:10.1128/msphere.00100-20
- Turner, 2013, Modeling effective transmission pathways and control of the worlds’ most successful parasite, Theor. Pop. Biol., 86, 50, 10.1016/j.tpb.2013.04.001 · doi:10.1016/j.tpb.2013.04.001
- Velázquez-Hernández, 2019, Knolwedge and practices regarding toxoplasmosis in housewives: a cross sectional study in a northern Mexican city, PLoS One, 14, 10.1371/journal.pone.0222094 · doi:10.1371/journal.pone.0222094
- Villegas, 2002, Susceptibility of interleukin-2-deficient mice to Toxoplasma gondii is associated with a defect in the production of gamma interferon, Infect. Immun., 70, 4757, 10.1128/IAI.70.9.4757-4761.2002 · doi:10.1128/iai.70.9.4757-4761.2002
- Waldeland, 1983, Temperature-sensitive mutants of Toxoplasma gondii: pathogenicity and persistence in mice, J. Parasitol., 69, 171, 10.2307/3281293 · doi:10.2307/3281293
- Walker, 2013, Sex and Eimeria: a molecular perspective, Parasitology, 140, 1701, 10.1017/S0031182013000838 · doi:10.1017/s0031182013000838
- Welsch, 2016, Discovery of potent and selective lLeads against Toxoplasma gondii dihydrofolate reductase via structure-based design, ACS Med. Chem. Lett., 7, 1124, 10.1021/acsmedchemlett.6b00328 · doi:10.1021/acsmedchemlett.6b00328
- Xu, 2013, DNA detection of Toxoplasma gondii with a magnetic molecular beacon probe via CdTe@Ni quantum dots as energy donor, J. Nanomater., 2013, 62, 10.1155/2013/473703 · doi:10.1155/2013/473703
- Yang, 2009, A quick and parallel analytical method based on quantum dots labeling for TORCH-related antibodies, Nanoscale Res. Lett., 4, 1469, 10.1007/s11671-009-9422-7 · doi:10.1007/s11671-009-9422-7
- Yardley, 2002, In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii, Antimicrob. Agents Chemother., 46, 929, 10.1128/AAC.46.3.929-931.2002 · doi:10.1128/aac.46.3.929-931.2002
- Zhang, 2014, Potent and selective inhibitors of CDPK1 from T. gondii and C. parvum based on a 5-aminopyrazole-4-carboxamide scaffold, ACS Med. Chem. Lett., 5, 40, 10.1021/ml400315s · doi:10.1021/ml400315s
- Zulpo, 2012, Oocyst shedding in cats vaccinated by the nasal and rectal routes with crude rhoptry proteins of Toxoplasma gondii, Exp. Parasitol., 131, 223, 10.1016/j.exppara.2012.04.006 · doi:10.1016/j.exppara.2012.04.006
Cited by
Li, D., Zhang, Y., Li, S., & Zheng, B. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1145114 · Cited by 22
Current control options and a way towards risk-based control of Toxoplasma gondii in the meat chain
Kuruca, L., Belluco, S., Vieira-Pinto, M., Antic, D., & Blagojevic, B. (2023) · Food Control · doi:10.1016/j.foodcont.2022.109556 · Cited by 21
Metadata
- Authors
- Smith, N. C., Goulart, C., Hayward, J. A., Kupz, A., Miller, C. M., & van Dooren, G. G.
- Venue
- International Journal for Parasitology
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 51
- Issue
- 2-3
- Pages
- 95-121
- ISSN
- 0020-7519 (ISSN-L)
- OpenAlex
- W3117286581
- Cited by
- 286
- References
- 280
- FWCI
- 21.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- National Health and Medical Research Council
- Australian Research Council
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Control of human toxoplasmosis. https://app.cochat.ai/papers/10.1016/j.ijpara.2020.11.001
- The paper
- Smith, N. C., Goulart, C., Hayward, J. A., Kupz, A., Miller, C. M., & van Dooren, G. G. (2021). Control of human toxoplasmosis. International Journal for Parasitology. https://doi.org/10.1016/j.ijpara.2020.11.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.